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INTRODUCTION
Independent i nvestigations have demonstrated the ex istence o f t elomere s hortened cel ls i n histologically normal t issues. T hus, w e pr opose t o c haracterize t he cellular c onsequences o f telomere shortening in normal cells. Since telomere shortening has been associated with cellular senescence and d ysfunctional t elomeres h ave b een as sociated w ith a ctivation o f t he D NA damage response pathway in tumor tissues, including premalignant lesions, we propose to assess senescence-associated m arkers an d D NA d amage response pa thway m arkers i n hi stologically normal h uman b reast tis sues th at d isplay either normal o r s hort te lomeres ( i.e. prior t o t umor formation). In addition, the proposed investigation has provided the investigator opportunities to interact with pathologists and oncologists to learn normal and abnormal breast morphology, the strengths and limitations of currently used breast cancer biomarkers, current standards of breast cancer t reatment an d t he s cientific rationale for o ngoing clinical tr ials. To date, all ta sks, as outlined in the Statement of Work, are on schedule.
Hypothesis and Rationale
Recent i nvestigations have d emonstrated t hat telomere l ength ab normalities ar e e arly an d frequent e vents i n t he m alignant t ransformation of c ancer, i ncluding br east, a nd e ven oc cur i n seemingly histologically normal breast tissues. In all, these data imply that there is a reservoir of genetically a ltered, yet h istologically n ormal, c ells w ithin n ormal b reast tis sues th at ma y represent f ertile ground f or t umor d evelopment. We h ypothesize that te lomere s hortening in normal epithelial cells induce cellular senescence; however, if this pathway is abrogated and the telomeres become critically short and, thereby dysfunctional, then the ends of the chromosomes will be recognized by the cell as double strand breaks and the DNA damage response pathway will be activated. Thus, we propose to further ch aracterize the molecular pathways of telomere shortening in the normal breast epithelium. The novel finding that telomeres shorten in a subset of h istologically n ormal T DLUs h as tr emendous p otential to illu minate th e me chanisms th at support the initiation of breast cancer and may lead to new prevention and treatment strategies. This hypothesis is being evaluated through three specific aims.
The first specific aim is to compare markers of cellular senescence in histologically normal TDLUs with either normal or short telomeres. We will determine the protein expression levels of senescence-associated markers (p16, p21, pR b, Maspin, macroH2A, Suv39h1, H3K9Me and HP1) b y immunohistochemistry in normal tissues obtained from r eduction mammoplasties and in matched tumor and histologically normal tissues at defined distances (1cm and 5cm) from the visible tumor margin.
The second specific aim is to determine if the DNA damage response pathway is activated in histologically TDLUs with short telomeres. Protein e xpression l evels f or m arkers i n t he D NA damage response pathway (pATM, pATR, pChk1, pChk2, PML, BRCA1, 53BP1, and γH2AX) will be a ssessed b y i mmunohistochemistry i n nor mal t issues ob tained f rom r eduction mammoplasties a nd in ma tched tu mor a nd h istologically n ormal tis sues a t d efined d istances (1cm and 5cm) from the visible tumor margin.
The third specific aim is to assess cellular senescence and activation of DNA damage response pathway in human mammary epithelial cells (HMEC) from tumor and histologically normal tissues by artificially shortening telomeres. Telomere Repeat Binding Factor 2 ( TRF2) will be over-expressed i n p rimary breast cel ls b y a l entiviral v ector to i nduce t elomere s hortening a nd cellular senescence and activation of DNA damage response pathway will be assessed.
II. KEY ACCOMPLISHMENTS

IIa. RESEARCH ACCOMPLISHMENTS
During the first year of this training grant, the investigator has:
• Written a nd obtained a pproval from t he O ffice o f H uman S ubjects R esearch Institutional Review Board at Johns Hopkins (November 12, 2009) and from the Human Research Protection Office of the U.S. Army Medical Research and Materiel Command (January 27, 2010) for collection of the clinical samples to be used in this investigation.
• Established collection protocols of clinical specimens for FISH and IHC experiments utilizing f ormalin-fixed, p araffin-embedded t issues a nd for p rimary c ell c ulture experiments utilizing freshly collected tissue. To date, histologically normal breast tissue from 1c m a nd 5c m f rom t he vi sible t umor m argin ha s be en obt ained from 27 w omen undergoing r adical mastectomy. A dditionally, h istologically n ormal b reast tis sue f rom the right and left breast has been obtained from 14 women undergoing bilateral reduction mammoplasty.
• Demonstrated that telomere shortening occurs specifically in luminal epithelial cells, but n ot in m yoepithelial c ells, in histologically n ormal te rminal d uctal lo bular u nits ( Figure 1 , A ppendix A ). S trikingly, t elomere shortening oc curs i n t he m ajority of histologically nor mal t erminal duc tal l obular uni ts a nalyzed f rom pa tients unde rgoing reduction mammoplasty, but the extent and degree of shortening varies by the individual. (Table 1 , Appendix B).
• Evaluated t elomere l ength i n 103 c ases of i nvasive breast can cer an d co rrelated telomere le ngth w ith e stablished mo lecular ma rkers. The s tudy demonstrated t hat telomere lengths were shorter in more aggressive breast cancer subtypes, such as luminal B, H ER-2 pos itive a nd triple-negative tu mors, s uggesting tu mor te lomere le ngth ma y have clinical utility as a prognostic and/or risk marker for breast cancer. (Appendix C).
IIb. TRAINING/EDUCATIONAL ACCOMPLISHMENTS
• Interacted and co llaborated with o ncologists, surgeons, p athologists, m olecular epidemiologists and other Ph.D. research scientists who specialize in the research and treatment of breast cancer.
• Attended weekly journal clubs, Oncology translational research seminars, breast cancer seminars, Pathology G rand R ounds, specific m eetings of t he H opkins B reast SPORE program and "sign-out" sessions with surgical pathologists.
• Given a s eminar on M ay 4, 2010 a t the Breast C ancer P rogram S eminar s eries sponsored b y t he H opkins B reast S PORE p rogram t itled " Telomere Length Alterations: Potential Clinical Utility in Breast Cancer".
• Presented r esearch findings internally a t t he D epartment of P athology Y oung Investigator's D ay ( April 8, 2010) a nd a t the 3 rd Annual S afeway Breast C ancer Retreat: Bench to Bedside to Population (June 25, 2010).
• Attended the American Association of Cancer Research (AACR) special conference titled "The R ole of Telomeres and T elomerase i n C ancer R esearch ( February 2 010; Ft. Worth, TX) and the AACR Annual Meeting (April 2010; Washington D.C.).
• Received experimental training in numerous methods including: fluorescence in situ hybridization, immunostaining, histopathology, primary cell culture, study design and statistical analysis.
IIc. PERFORMANCE ACCOMPLISHMENTS
Experimental Milestones Specific Aim 1 (5 tasks)
Task 1 Months 1-6
In Progress • Establish validated pr otocols f or IHC us ing t he a ntibodies f or s enescence-associated markers. o Positive (senescent) and negative (non-senescent) control cells have been generated from the WI-38 fibroblast c ell lin e a nd f rom h uman mammary epithelial c ells o btained f rom surgical specimens. Cell blocks have been generated to be used for staining purposes. All senescence-associated antibodies have been identified and commercially obtained. in press (Appendix C).
IV. CONCLUSIONS
To date, all t asks; a s o utlined i n t he S tatement of W ork a re on s chedule. The a ppropriate approvals f or t he collection of t he c linical s amples t o be us ed i n t his i nvestigation ha ve be en obtained. Tissue collection protocols have been established and procurement of clinical samples has b een i nitiated. T he ac crual rates for obt aining tis sues from r adical ma stectomies and reduction ma mmoplasties are o n t arget. The in vestigator h as d emonstrated th at te lomere shortening o ccurs s pecifically in lu minal e pithelial c ells, b ut n ot in myoepithelial c ells, in histologically normal te rminal d uctal l obular uni ts a nd oc curs i n t he m ajority of hi stologically normal terminal ductal lobular units analyzed from patients undergoing reduction mammoplasty. However, the extent and degree of telomere shortening varies by the individual. Additionally, the investigator ha s s hown t hat t elomere l engths are shorter i n the more a ggressive b reast can cer subtypes, s uch a s l uminal B , H ER-2 pos itive and t riple-negative t umors, s uggesting t umor telomere le ngth ma y h ave u tility as a p rognostic a nd/or risk ma rker f or breast c ancer. A manuscript containing these results has been accepted for publication in the Modern Pathology, which i s c urrently i n p ress. T he i nvestigator is p rogressing w ith all o f h is e ducational and training goals. It is well established that telomere shortening is present in the majority of in situ and invasive carcinomas (5), including breast (6, 7). Thus, telomere shortening is an early event in malignant transformation. In addition to tumor initiation, short dysfunctional telomeres may also affect disease progression. Previous studies have shown reduced telomere length in Grade 3 tumors (8), reduced telomere DNA content, a surrogate for telomere length, correlates with aneuploidy and lymph node metastasis (9), and shorter telomeres were associated with higher stage and histological grade (10) . A retrospective study (n=77) demonstrated that short telomeres were associated with tumor size, nodal involvement, TNM stage and was an independent predictor of 5-year overall survival and 5-year breast cancer-free survival. (11) . A larger population-based prospective study (n=530) showed that short telomeres conferred a relative hazard of breast cancer recurrence of 2.88, after adjusting for prognostic factors and adjuvant therapies (12) . However, none of these studies took into consideration specific breast cancer subtypes that are now used to help guide treatment decisions.
Four main molecular classes of breast cancer were first identified by gene expression profiling (13) . On further validation, these subtypes correlate well with clinical characterization of ER, PR and HER-2 protein expression status (14, 15) . These groups are luminal A carcinomas (ER and PR positive, HER-2 negative), luminal B carcinomas (ER or PR positive, HER-2 positive), HER-2 carcinomas (ER and PR negative, HER-2 positive) and triple-negative carcinomas (ER/PR/HER-2 negative). Important for clinical care, these subtypes predict prognosis and therapeutic response (16) (17) (18) . Luminal A tumors respond well to selective estrogen receptor modulators (SERMs), such as tamoxifen (19) . Luminal B tumors tend to be less sensitive to hormonal therapies and thus carry a worse prognosis compared to the luminal A tumors. HER-2 positive cancers tend to be high grade, aggressive, and carry a poor prognosis; however, they respond well to trastuzumab, an anti-HER-2 monoclonal antibody. Conversely, triple-negative carcinomas are extremely aggressive and currently do not respond to any hormonal or antibodybased targeted therapy (20) .
The objective of this study was to evaluate telomere lengths in subtypes of breast carcinoma.
This was accomplished using a fluorescence in situ hybridization (FISH) assay that allows telomere length assessments in formalin-fixed, paraffin-embedded archival material, while providing single cell resolution and keeping intact tissue architecture. We evaluated telomere length in 103 cases of invasive breast cancer and correlated telomere length with established molecular markers.
MATERIALS AND METHODS
Case Selection
All of the 103 cases evaluated in this study were incident breast carcinomas that were surgically 
Tissue Microarray Construction
For the majority of the cases (n=72), tissue microarrays were constructed as previously described (21, 22) . Briefly, each tissue microarray consisted of 99 tissue cores, each 1.4 mm in diameter.
These cores were arranged in 9 rows and 11 columns. Column 6 consisted of various unrelated control tissues, leaving 90 cores on the array for breast carcinoma samples. For each carcinoma case, 5 areas were identified on the hematoxylin and eosin slides, punched from the corresponding donor blocks, and placed on the array. Among the 5 samples of each case, we attempted to include normal tissue and carcinoma in situ in 1 sample if possible, leaving 4 to 5 cores of invasive ductal carcinoma per case. Any case that displayed a processing artifact was excluded. Additionally, as not to exhaust the tissue, small size (<1 cm) cases were excluded. For an additional 31 cases, whole sections from surgical specimen blocks were used.
Immunohistochemistry
All immunohistochemistry was performed as previously described (21, 22 (51% to 75%), and 4+ (76% to 100%). Cases with membranous or cytoplasmic labeling in >25% of neoplastic cells were considered positive. For EGFR, cases were scored on the basis of percentage of positive cells: 1+ (1% to 25%), 2+ (26% to 50%), 3+ (51% to 75%), and 4+ (76% to 100%). Any strong membranous staining for EGFR was considered a positive, generally labeling 10-50% of neoplastic cells. p53 (monoclonal, Ventana) and Ki-67 (monoclonal, Ventana) immunohistochemistry were also performed and only nuclear labeling was scored. For p53, labeling of >30% of nuclei was considered aberrant overexpression, and labeling of less than 30% of nuclei was considered negative for aberrant overexpression; 30% labeling of nuclei was considered equivocal. For Ki-67, labeling of ≥20% of nuclei was considered high and labeling of <20% of nuclei was considered low.
Telomere FISH
Telomere lengths were assessed by fluorescence staining for telomeric DNA as previously described (6, 23) . Briefly, deparaffinized slides were hydrated through a graded ethanol series, placed in deionized water, followed by deionized water plus 0.1% Tween-20. Slides were then placed in citrate buffer (catalog No. H-3300; Vector Laboratories), and steamed for 14 minutes (Black and Decker Handy Steamer Plus; Black and Decker), removed, and allowed to cool at room temperature for 5 minutes. Slides were then placed in PBS with Tween (catalog No. P-3563; Sigma) for 5 minutes. Slides were thoroughly rinsed with deionized water, followed by 95% ethanol for 5 minutes, and then air-dried. Twenty-five µl of a Cy3-labeled telomerespecific peptide nucleic acid (0.3-µg/ml peptide nucleic acid in 70% formamide, 10 mmol/L Tris, pH 7.5, 0.5% B/M Blocking reagent (catalog No. 1814-320; Boehringer-Mannheim) was applied to the sample, which was then coverslipped, and denaturation was performed by incubation for 4 minutes at 83°C. Slides were then moved to a dark, closed container for hybridization at room temperature for 2 hours. Coverslips were then carefully removed and the slides were washed twice in peptide nucleic acid wash solution (70% formamide, 10 mmol/L Tris, pH 7.5, 0.1% albumin (from 30% albumin solution, catalog No. A-7284; Sigma)) for 15 minutes each, then rinsed in PBS with Tween, and thoroughly rinsed in deionized water. Slides were drained and counterstained with 4'-6-diamidino-2-phenylindole (DAPI) (500 ng/ml in deionized water, Sigma Chemical Co. Cat #D-8417) for 5 minutes at room temperature, mounted with Prolong anti-fade mounting medium (catalog No. P-7481; Molecular Probes), and imaged.
The peptide nucleic acid probe complementary to the mammalian telomere repeat sequence was obtained from Applied Biosystems, and has the sequence (N-terminus to C-terminus)
CCCTAACCCTAACCCTAA with an N-terminal covalently linked Cy3 fluorescent dye. As a positive control for hybridization efficiency, a FITC-labeled peptide nucleic acid probe having the sequence ATTCGTTGGAAACGGGA with specificity for human centromeric DNA repeats (CENP-B binding sequence) was also included in the hybridization solution (24) .
Microscopy and Telomere Length Assessment
Slides were imaged with a Nikon 50i epifluorescence microscope equipped with X-Cite series 120 illuminator (EXFO Photonics Solutions Inc., Ontario, CA). Fluorescence excitation/emission filters were as follows: Cy3 excitation, 546 nm/10 nm BP; emission, 578 nm LP (Carl Zeiss 
Statistical Analysis
For all analyses, the normal and long telomere groups were combined and compared to the short telomere group. Results were compared using two-sided Fisher exact tests. P-values < 0.05 were considered to be significant. SAS 9.2 and JMP ® statistical packages (SAS Institute, Cary, NC)
were used for all analyses. Table 1 lists the clinical and pathological characteristics of the study population. Of the 103 subjects included in this study, the mean age at diagnosis for all patients was 56 years (range; 30-94 years). The patients were predominantly Caucasian (57%) or African American (31%). Elston grading of the tumors showed that 4% were Grade I, 23% were Grade II and 73% were Grade III. According to the established criteria of the American Joint Committee on Cancer (AJCC 2007), 21% were Stage I, 59% were Stage II, 18%
RESULTS
Clinical and Pathological Characteristics:
were Stage III and 1% were Stage IV. Interestingly, the short telomere length group tended to be younger and contained a greater proportion of African American women when compared to the normal/long group; however, these differences did not reach statistical significance.
Telomere-FISH in Breast Tumors:
Telomere length was qualitatively scored and grouped into short (n=88), normal (n=13) or long (n=2) categories. Figure 1A shows a representative example of a breast cancer with short telomeres as indicated by the diminished telomere signals in the cancer cells when compared to either stromal cells or myoepithelial cells in an adjacent terminal ductal lobular unit. As shown in Figure 1B , the cancer cells from this breast cancer show comparable telomere intensities to that observed in the surrounding benign stroma. Figure 1C, shows an example of a breast tumor with increased telomere signals in the cancer cells when compared to the surrounding benign stromal cells. Table 1 shows the clinical and pathological characteristics for the subset of patients with short telomeres (n=88) and the subset of patients with either normal or long telomeres (n=15).
Hormone Receptor Expression Characteristics: Table 2 were 37 triple-negative carcinoma cases which were negative for ER, PR, and HER-2. For 29 of the triple-negative cases, immunohistochemical data on CK 5/6 and EGFR expression was available, allowing assessment of the basal phenotype. Eighteen of these cases showed staining for CK 5/6 and/or EGFR (basal) and 11 cases were CK 5/6 and EGFR negative (non-basal).
Within this triple-negative group, there was no difference in the proportion of cases with short telomeres between the subset of cases determined to be basal (94%) and non-basal (91%)
phenotypes. As shown in Figure 2 , the luminal B cancers (93%), HER-2 cancers (90%) and the triple-negative cancers (95%) had an increased proportion of cases with short telomeres when compared to the luminal A cancers (50%); these were all statistically significant differences (p=0.002, p=0.011 and p=0.0003, respectively).
DISCUSSION
The first principal conclusion emerging from this study is the observation that telomere shortening is associated with other established breast cancer prognostic factors. It is well established that breast cancer patients with tumors that are ER and/or PR negative have an increased risk of mortality (25) (26) (27) . We observed an increased proportion of tumors in the short telomere group that were negative for ER and PR. Although temporality cannot be determined, these results suggest that telomere shortening may contribute to the selection of cells capable of growing in the absence of hormone receptors. Another molecular marker associated with poor breast cancer prognosis is the presence of mutations in the p53 gene, predominantly mis-sense mutations leading to conformational alterations of the protein and accumulation in tumor cell nuclei (28) (29) (30) . We observed an increased proportion of tumors in the short telomere group that were p53 positive, suggesting that less aggressive tumors are characterized by normal length telomeres and no mutations in the p53 gene. Conversely, short, dysfunctional telomeres may provide a strong selective pressure for abrogation of the p53 pathway. Normally, critical telomere shortening leads to p53-dependent tumor suppressive cellular responses, such as cellular senescence and apoptosis (2) . However, if this checkpoint is abrogated and the telomeres are partially stabilized by the up-regulation of telomerase, then further proliferation occurs and genomic instability may accumulate (31, 32) .
The second principal conclusion emerging from this study is that telomere shortening occurs in the vast majority of luminal B, HER-2 and triple-negative tumors, but in a smaller fraction of the luminal A type tumors. A recent large patient cohort demonstrated that luminal A tumors are associated with a lower risk of local or regional recurrence when compared to the other molecular subtypes (18) . It has long been recognized that breast adenocarcinomas are characterized by genomic instability. The molecular mechanisms leading to genomic instability are not fully elucidated; however, one potential initiator of genomic instability is telomere dysfunction due to critical telomere shortening (4, 33) . Thus, telomere shortening may be reflective of the degree of underlying genomic instability, a feature shared by higher grade HER-2 and triple-negative carcinomas (34) . Another possibility is that telomere shortening follows tumor progression as evidenced by the association with higher stage and histological grade (8, 10, 11) . It is noteworthy that recent data have demonstrated that not only can short telomeres lead to telomere dysfunction, but abnormally long telomeres may also do so (35, 36) . In this context, we previously demonstrated the presence of alternative lengthening of telomeres, a recombination-based mechanism that lengthens telomeres, in three cases of breast carcinoma (21) . Interestingly, all three cases were also HER-2 positive, suggesting a possible common underlying mechanism. The significance of long telomeres in cancers lacking evidence of the alternative lengthening of telomeres phenotype is currently not clear and would need to be addressed in future studies.
This study is the first assessment of telomere lengths in breast cancer subtypes. Additionally, we analyzed telomere lengths directly, at the single cell level, within breast cancer tissues using a FISH assay. Previous studies have measured telomeres using bulk assays such as Southern blot and terminal restriction fragment analysis (8) , quantitative PCR (10) or with a chemiluminescent-based slot blot assay that measures telomere DNA content, a proxy of telomere length (9, 11, 12) . These types of measurements do not allow for single cell resolution.
Study limitations include the absence of small tumors (<1cm), thus selecting for higher stage and histological grade cases, and the limited demographic and lifestyle information, as this was obtained retrospectively. Additionally, the lack of complete data on follow-up time, due to the fact that part, but not all, of the patients' treatment occurred at our Institution, prevented us from determining an association between telomere length and outcome.
In conclusion, we have demonstrated that telomere lengths vary among different subtypes of breast cancer in a manner consistent with their aggressiveness. Prospective studies are needed to further evaluate the usefulness of telomere length as a prognostic and/or predictive marker of disease progression and treatment response within the various subtypes and determine temporality.
*There are no statistically significant differences in any of the clinical or pathological characteristics between the telomere length groups **Eighteen women are missing weight data P-values were determined using two-sided Fisher's Exact Tests.
